Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Observational Study of Switching from Natalizumab to Immunomodulatory Drugs.
Villaverde-González R, Gracia Gil J, Pérez Sempere A, Millán Pascual J, Marín Marín J, Carcelén Gadea M, Gabaldón Torres L, Moreno Escribano A, Candeliere Merlicco A. Villaverde-González R, et al. Among authors: millan pascual j. Eur Neurol. 2017;77(3-4):130-136. doi: 10.1159/000453333. Epub 2017 Jan 5. Eur Neurol. 2017. PMID: 28052269
Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
Arnal-Garcia C, García-Montero MR, Málaga I, Millán-Pascual J, Oliva-Nacarino P, Ramió-Torrentà L, Oreja-Guevara C. Arnal-Garcia C, et al. Among authors: millan pascual j. Eur J Paediatr Neurol. 2013 Jan;17(1):50-4. doi: 10.1016/j.ejpn.2012.09.004. Epub 2012 Sep 27. Eur J Paediatr Neurol. 2013. PMID: 23021975
Psoriasis during natalizumab treatment for multiple sclerosis.
Millán-Pascual J, Turpín-Fenoll L, Del Saz-Saucedo P, Rueda-Medina I, Navarro-Muñoz S. Millán-Pascual J, et al. J Neurol. 2012 Dec;259(12):2758-60. doi: 10.1007/s00415-012-6713-1. Epub 2012 Oct 25. J Neurol. 2012. PMID: 23096069
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
Meca-Lallana J, Ayuso T, Martínez-Yelamos S, Durán C, Contreras Martín Y, Herrera Navarro N, Pérez Sempere A, Álvarez-Cermeño JC, Millán Pascual J, Meca-Lallana V, Romero Sevilla R, Ricart J. Meca-Lallana J, et al. Among authors: millan pascual j. Eur Neurol. 2020;83(1):25-33. doi: 10.1159/000505778. Epub 2020 Mar 18. Eur Neurol. 2020. PMID: 32187609 Free PMC article.
Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
Fernandez-Diaz E, Perez-Vicente JA, Villaverde-Gonzalez R, Berenguer-Ruiz L, Candeliere Merlicco A, Martinez-Navarro ML, Gracia Gil J, Romero-Sanchez CM, Alfaro-Saez A, Diaz I, Gimenez-Martinez J, Mendez-Miralles MA, Millan-Pascual J, Jimenez-Pancho J, Mola S, Sempere AP. Fernandez-Diaz E, et al. Among authors: millan pascual j. Ann Clin Transl Neurol. 2021 Feb;8(2):385-394. doi: 10.1002/acn3.51282. Epub 2020 Dec 25. Ann Clin Transl Neurol. 2021. PMID: 33369288 Free PMC article.
SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.
Arrambide G, Llaneza-González MÁ, Costa-Frossard França L, Meca-Lallana V, Díaz EF, Moreno-Torres I, García-Domínguez JM, Ortega-Suero G, Ayuso-Peralta L, Gómez-Moreno M, Sotoca-Fernández JJ, Caminero-Rodríguez AB, Rodríguez de Antonio LA, Corujo-Suárez M, Otano-Martínez MA, Pérez-Miralles FC, Reyes-Garrido V, Ayuso-Blanco T, Balseiro-Gómez JJ, Muñoz-Pasadas M, Pérez-Molina I, Arnal-García C, Domingo-Santos Á, Guijarro-Castro C, Íñiguez-Martínez C, Téllez Lara N, Castellanos-Pinedo F, Castillo-Triviño T, Cerdán-Santacruz DM, Pérez-Sempere Á, Torres BS, Álvarez de Arcaya A, Costa-Arpín E, Durán-Ferreras E, Fragoso-Martínez M, González-Platas M, Landete Pascual L, Millán-Pascual J, Oreja-Guevara C, Meca-Lallana JE. Arrambide G, et al. Among authors: millan pascual j. Neurol Neuroimmunol Neuroinflamm. 2021 Jun 24;8(5):e1024. doi: 10.1212/NXI.0000000000001024. Print 2021 Jul. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34168057 Free PMC article.
Treatment with natalizumab during pregnancy in multiple sclerosis: The experience of implementing a clinical practice protocol (NAP-30).
Valero-López G, Millán-Pascual J, Iniesta-Martínez F, Delgado-Marín JL, Jimenez-Veiga J, Tejero-Martín AB, León-Hernández A, Zamarro-Parra J, Morales-Ortiz A, Meca-Lallana JE. Valero-López G, et al. Among authors: millan pascual j. Mult Scler Relat Disord. 2022 Oct;66:104038. doi: 10.1016/j.msard.2022.104038. Epub 2022 Jul 7. Mult Scler Relat Disord. 2022. PMID: 35870370 Free article.
Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain.
Fernández O, Agüera E, Izquierdo G, Millán-Pascual J, Ramió I Torrentà L, Oliva P, Argente J, Berdei Y, Soler JM, Carmona O, Errea JM, Farrés J; Group on Adherence to IFNb-1b in Spain. Fernández O, et al. Among authors: millan pascual j. PLoS One. 2012;7(5):e35600. doi: 10.1371/journal.pone.0035600. Epub 2012 May 16. PLoS One. 2012. PMID: 22615737 Free PMC article.
NQO1 gene rs1800566 variant is not associated with risk for multiple sclerosis.
Agúndez JA, García-Martín E, Martínez C, Benito-León J, Millán-Pascual J, Calleja P, Díaz-Sánchez M, Pisa D, Turpín-Fenoll L, Alonso-Navarro H, Ayuso-Peralta L, Torrecillas D, Plaza-Nieto JF, Jiménez-Jiménez FJ. Agúndez JA, et al. Among authors: millan pascual j. BMC Neurol. 2014 Apr 23;14:87. doi: 10.1186/1471-2377-14-87. BMC Neurol. 2014. PMID: 24755231 Free PMC article.
Predictors of burden and depression among caregivers of relapsing-remitting MS patients in Spain: MS Feeling study.
Meca-Lallana J, Mendibe M, Hernández-Clares R, Caminero AB, Mallada-Frechin J, Dávila-Gonzalez P, Garcés-Redondo M, Gómez M, Millán-Pascual J, Soriano-Hernández G, Amigo-Jorrín Mdel C. Meca-Lallana J, et al. Among authors: millan pascual j. Neurodegener Dis Manag. 2016 Aug;6(4):277-87. doi: 10.2217/nmt-2016-0014. Epub 2016 Aug 2. Neurodegener Dis Manag. 2016. PMID: 27480482
40 results